Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025
bởiStephen Padilla
The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.
07 Jan 2025

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
07 Jan 2025
bởiAudrey Abella
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
07 Jan 2025







